[go: up one dir, main page]

FI963049L - Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi - Google Patents

Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi Download PDF

Info

Publication number
FI963049L
FI963049L FI963049A FI963049A FI963049L FI 963049 L FI963049 L FI 963049L FI 963049 A FI963049 A FI 963049A FI 963049 A FI963049 A FI 963049A FI 963049 L FI963049 L FI 963049L
Authority
FI
Finland
Prior art keywords
manufacture
treatment
medicinal products
products intended
bleeding due
Prior art date
Application number
FI963049A
Other languages
English (en)
Swedish (sv)
Other versions
FI963049A0 (fi
FI117850B (fi
Inventor
Kristof Chwalisz
Klaus Stoeckemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI963049A0 publication Critical patent/FI963049A0/fi
Publication of FI963049L publication Critical patent/FI963049L/fi
Application granted granted Critical
Publication of FI117850B publication Critical patent/FI117850B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI963049A 1995-02-02 1996-08-01 Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi FI117850B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP9500394 1995-02-02
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (3)

Publication Number Publication Date
FI963049A0 FI963049A0 (fi) 1996-08-01
FI963049L true FI963049L (fi) 1996-10-01
FI117850B FI117850B (fi) 2007-03-30

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963049A FI117850B (fi) 1995-02-02 1996-08-01 Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi

Country Status (20)

Country Link
US (1) US6451780B1 (fi)
EP (1) EP0806952B1 (fi)
JP (1) JPH10512889A (fi)
KR (1) KR100370908B1 (fi)
AT (1) ATE235907T1 (fi)
AU (1) AU714959B2 (fi)
CA (1) CA2186953C (fi)
DE (1) DE59510626D1 (fi)
DK (1) DK0806952T3 (fi)
ES (1) ES2196063T3 (fi)
FI (1) FI117850B (fi)
HU (1) HU226276B1 (fi)
MX (1) MX9603889A (fi)
NO (1) NO964155L (fi)
NZ (1) NZ287024A (fi)
PL (1) PL316533A1 (fi)
PT (1) PT806952E (fi)
SK (1) SK282570B6 (fi)
UA (1) UA37259C2 (fi)
WO (1) WO1996023503A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281363A (zh) * 1997-11-14 2001-01-24 阿克佐诺贝尔公司 孕激素-抗孕激素体系
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
PT1229906E (pt) 1999-08-31 2008-01-18 Bayer Schering Pharma Ag Mesoprogestinas para o tratamento e prevenção de distúrbios ginecológicos hormonodependentes benignos
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
CA2569738A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
US8569274B2 (en) * 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
US20090118253A1 (en) * 2007-11-05 2009-05-07 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
JP6343619B2 (ja) 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
EP3394078A4 (en) 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
EP3394079A4 (en) 2015-12-23 2019-08-21 Oric Pharmaceuticals, Inc. INHIBITORS OF GLUCOCORTICOIDREZEPTORS
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN111690031B (zh) 2016-10-07 2021-06-01 欧瑞克制药公司 糖皮质激素受体抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1918092A (en) * 1992-05-06 1993-11-29 Medical College Of Hampton Roads, The Minimizing progestin associated breakthrough bleeding
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
PT806952E (pt) 2003-08-29
DK0806952T3 (da) 2003-06-16
NZ287024A (en) 2001-03-30
EP0806952B1 (de) 2003-04-02
ES2196063T3 (es) 2003-12-16
NO964155D0 (no) 1996-10-01
DE59510626D1 (de) 2003-05-08
AU714959B2 (en) 2000-01-13
HU9602668D0 (en) 1996-11-28
WO1996023503A1 (de) 1996-08-08
HU226276B1 (en) 2008-07-28
NO964155L (no) 1996-10-01
EP0806952A1 (de) 1997-11-19
CA2186953A1 (en) 1996-08-08
ATE235907T1 (de) 2003-04-15
FI963049A0 (fi) 1996-08-01
JPH10512889A (ja) 1998-12-08
SK282570B6 (sk) 2002-10-08
MX9603889A (es) 1997-04-30
AU2561195A (en) 1996-08-21
US6451780B1 (en) 2002-09-17
CA2186953C (en) 2009-11-10
KR970704451A (ko) 1997-09-06
PL316533A1 (en) 1997-01-20
SK121996A3 (en) 1997-05-07
FI117850B (fi) 2007-03-30
KR100370908B1 (ko) 2003-04-10
UA37259C2 (uk) 2001-05-15
HUT75930A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
FI963049L (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
FI20115753L (fi) Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon
TR199600792A2 (tr) Dihaloazolopirimidinlerin hazirlanmasina yönelik proses.
FI963831A7 (fi) Farmaseuttinen yhdistelmävalmiste hormonaalista ehkäisyä varten
NO903088L (no) Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
ITRM920412A0 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO974034D0 (no) Anatomisk formet, sammensatt sanitetsbind
NO900697D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
AU8553898A (en) Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
NO871190D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive substituerte anilider.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO175746C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktivt 1-etyl-fenoksatiin-10,10-dioksyd
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
FR2722131B1 (fr) Procede de preparation de melanges aqueux agrileux pompables
NO904470D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater.
TR199501663A2 (tr) Farmasötik bilesimlerin hazirlanmasi icin islemler.
TR199501664A2 (tr) Farmasötik bilesimlerin hazirlanmasi icin islemler.
ES1021127Y (es) Dispositivo para la formacion de torundas sanitarias radio-opacas.
NO890506L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kloranilin-derivater.
NO891677D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenetanolamin-derivater.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117850

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

MM Patent lapsed